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Human carbonic anhydrases (hCAs, EC 4.2.1.1) IX and XII are overexpressed in a wide variety of 
cancers and are considered available drug targets for anti-tumor therapy since their inhibition has 
been shown to reduce tumor growth and metastasis. A set of coumarin derivatives (1-10) and 
several 1-aryl and 2-aryl-substituted chromeno[4,3-c]pyrazol-4-ones (11-37) and pyrano[4,3-
c]pyrazol-4-ones (38-39) were synthesized and tested against the tumor-associated hCAs IX and 
XII and the cytosolic isoforms hCAs I and II. Several compounds were potent (Ki < 41 nM) and 
selective inhibitors of the hCA IX (13, 14, 19, 21, 25, 31, 33, 37 and 39), some derivatives (6, 11 
and 17) were active against both hCA IX and XII isoforms (Ki= 5.6-9.6 nM), while none were 
effective against the off-target cytosolic hCAs I and II. Some selected inhibitors (6, 11, 13, 19, 21, 
25, 31 and 39) showed activity as antiproliferative agents on HT-29 colon cancer cell lines both in 
normoxic and hypoxic conditions. This finding led us to hypothesize for these derivatives more than 
one mechanism of action, involving hCAs IX and XII inhibition in hypoxia and other not identified 
target(s) in normoxia. 
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Human carbonic anhydrases (hCAs, EC 4.2.1.1) are metallo-enzymes that regulate physiological 
functions connected to carbon dioxide/bicarbonate transport, pH, electrolyte secretion, and 
biosynthetic reactions, thus they influence many metabolic processes [1-2]. hCAs are divided into at 
least 15 isoforms differing in their molecular properties, subcellular localization and tissue 
distribution. hCA isoforms IX and XII are membrane-bound enzymes whose expression is strongly 
induced by hypoxia [3] that occurs in different types of solid tumors, such as glioma, breast cancer 
and colon carcinoma. Hypoxia shifts metabolism toward glycolysis and anaerobic fermentation thus 
affording a high production of lactic acid [3]. These conditions, together with an excessive 
formation of carbon dioxide, induce progressive acidification of the extracellular environment due 
to extrusion of protons from the cell and the entrance of bicarbonate ions [1-6]. Protons and 
bicarbonate ions are produced by carbon dioxide hydration catalyzed by the transmembrane hCAs 
IX and XII. Both these hCA isoforms contribute to tumor progression by maintaining a more 
alkaline resting intracellular pH and the acidic extracellular pH. These conditions up-regulate 
proteases, angiogenic and cell-growth factors, and impaired immune functions [5-9]. 
 
hCA IX 
activity has also been associated with chemoresistance which may be due to two mechanisms [10]. 
First, hCA IX inhibits apoptosis by maintaining a normal intracellular pH in response to 
chemotherapy-induced acidosis. Second, hCA IX-induced extracellular acidosis negatively impacts 
efficacy of weakly basic anticancer drugs by reducing their cellular uptake.  
Acetazolamide (AZA) and other sulfonamide-containing hCA inhibitors were reported to reduce 
tumor growth and to delay tumor development. However, AZA and the classical aromatic 
sulfonamides are non-selective inhibitors, thus leading to side effects by blocking the 
physiological relevant cytosolic isozymes hCA I and II. Hence, several studies are being carried 
out to identify new selective inhibitors for the tumor-associated hCA isoforms which are 
considered promising targets for effective and safer agents in cancer therapy [8-13]. 
Up to now several classes of inhibitors have been disclosed [1, 11, 13, 15], for example 
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sulfonamides, metal-complexing anions, phenols and 2H-chromen-2-one derivatives, simply 
referred to as coumarins [16-20]. Within the latter class, the unsubstituted coumarin possesses 
potencies spanning the medium to high micromolar range. In particular, it showed Ki values of 3.1 
and 9.2 M at the highly abundant hCAs I and II, respectively, while lower potencies were found 
for membrane-bound hCA IX and XII isoforms (Ki> 500 M) [16]. Insertion of substituents on 
the coumarin scaffold significantly enhanced inhibitory activity. In particular, the presence of ester 
functions or a carboxylic group at position 3, alone or combined with small substituents on the 
fused benzo ring (Fig. 1, 3-carboxy-substituted coumarin series), ameliorated the potency toward 
the tumor-associated hCA IX and XII, shiftinh the Ki values to the low micromolar range (0.047-
9.9 M) [16]. These data suggested that further decoration of coumarin might enhance potency 
and selectivity for the two hCA isoforms.
 
Therefore, to continue our study in the field of hCA IX 
and XII inhibitors [21] we chose the coumarin scaffold for investigation. Thus, we synthesized 
compounds 1-10 (Fig. 1) which bear at position 3 the acetyl group, in place of the less stable ester 
function present in the previously reported 3-carboxycoumarins [16], and diverse substituents at 












Fig. 1. Design of 2H-chromen-2-one derivatives 1-10 and their analogs chromeno[4,3-c]pyrazol-4-





Next, several chromeno[4,3-c]pyrazol-4-one derivatives (11-37) were synthesized and biologically 
tested. To explore the structural requirements of different areas around the tricyclic core, different 
substituents with diverse steric bulk and lipophilicity were placed at position 1 or 2 (R= Ar, CH2Ph, 
Me) and 3 (R3= H, Me, CH2Ph), and on the fused benzo ring (X= H, Br, NO2, Cl, NH-R’) (Fig. 1). 
Finally, the pyrano[4,3-c]pyrazoles 38 and 39 were designed to evaluate how replacement of the 
fused benzo ring with the smaller methyl group affected complementarity with the hCAs. 
 
2. Results and discussion 
2.1.Chemistry 
3-Acetylchromen-2-one (1) was purchased from Sigma-Aldrich while the other target compounds 
2-39 were prepared as drawn in Schemes 1-6. The 3-acetylchromen-2-ones 2 [22] and 3 (Scheme 1) 
ensued from a Knoevenagel condensation between 5-substituted 2-hydroxybenzaldehydes and ethyl 
acetoacetate, carried out  in the presence of piperidine and under microwave irradiation. Nitration of 









Scheme 1. Reagents and conditions: a) piperidine, mw, 120 °C; b) 90% HNO3, -10 °C. 
 
 
The synthesis of the 4-substituted 3-acetylchromen-2-one derivatives 5-10 and 3-methyl-1-aryl-



















Scheme 2. Reagents and conditions: a) ethyl acetoacetate sodium salt, anhydrous Et2O (X= H) or 
toluene (X= Br), reflux; b) KNO3, 96% H2SO4, 0 °C; c) (MeO)2SO2, anhydrous acetone, K2CO3, 
mw, 125 °C; d) EtOH, reflux; e) Ar-NHNH2.HCl, NEt3, EtOH, reflux; f) p-TsOH, xylene, reflux. 
 
The 3-acetyl-4-hydroxychromen-2-one 5 and its 6-bromo derivative 6 were synthesized as 
previously reported, i.e. by reacting the suitable acetylsalicyloyl choride with the sodium salt of 
ethyl acetoacetate [23, 24]. This method was not employed to prepare the 6-nitro-derivative 7 [24] 
which was obtained by nitration of derivative 5. The 4-hydroxy group of 5 and 6 was then alkylated 
with dimethylsulfate in anhydrous acetone and in the presence of potassium carbonate, under 
microwave-assisted conditions, to yield the 4-methoxy derivatives 8 and 9. The latter afforded the 
4-ethoxy derivative 10 after heating in refluxing absolute ethanol. The 3-acetyl-4-hydroxy-
chromen-2-ones 5-7 were used as starting material to prepare the 1-aryl-3-methylchromeno[4,3-
c]pyrazol-4-one 11-14 [23] and 17 [24]. Briefly, compounds 5-7 were reacted with suitable 
arylhydrazines in boiling ethanol to give the corresponding arylhydrazones [23, 24] which were 
cyclized in refluxing xylene and in the presence of para-toluensulfonic acid to provide derivatives 
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11-14, 17. The same synthetic pathway was used to prepare the 1-(2-carboxyphenyl)-substituted 


















Scheme 3. Reagents and conditions: a) Ar-NHNH2, EtOH, reflux; b) Cu(AcO)2, CuSO4, EtOH, 
reflux; c) from 19, H2, Pd/C, Parr apparatus 33 psi. 
 
 
The tricyclic derivatives 16 and 18-20 (Scheme 3) were synthesized from the 3-acetylchromen-2-
ones 1-4 which were reacted with arylhydrazines to afford the relative arylhydrazones 41-44. The 
latter were cyclized by oxidation with a mixture of cupric sulfate and cupric acetate to give the 
chromeno[4,3-c]pyrazoles 16, 18-20. Catalytic reduction (Pd/C) of the 8-nitro derivative 19 
provided the corresponding 8-amino derivative 21 which, besides being a target compound, was 




 R1 R2 R 
16, 41 H H COOH 
18, 42 H Cl H 
19, 43 NO2 H H 
20, 44 NO2 Cl H 























Scheme 4. Reagents and conditions: a) excess of MeI, K2CO3, CH3CN; b) RCOCl, NEt3, anhydrous 
CH2Cl2, rt; c) PhNCO, anhydrous THF, reflux; d) PhCHO, anhydrous ZnCl2, anhydrous THF, 
reflux, N2; e) NaBH4, MeOH, reflux, N2. 
 
Reaction of 21 with an excess of methyl iodide furnished a mixture of the 8-methylamino- and 8-
dimethylamino derivatives 22 and 23, respectively, which were separated by column 
chromatography. When compound 21 was reacted with acyl chlorides or phenylisocyanate, the 
corresponding 8-amido- (24, 25) or 8-phenylureido- (26) derivatives were obtained. The 8-
benzylamino- substituted compound 27 was synthesized by treatment of 21 with benzaldehyde and 
subsequent reduction of the Schiff’s base 45 with sodium borohydride. The 1-
benzylchromenopyrazol-4-one derivative (28) (Scheme 5) was prepared by reacting 3-acetyl-4-
hydroxychromen-2-one (5) with benzylhydrazine in refluxing ethanol. The 2-phenylchromeno[4,3-
c]pyrazol-4-one derivatives 32-34 (Scheme 5) were obtained starting from the 3-acetyl-4-














Scheme 5. Reagents and conditions: a) Ph-CH2NHNH2 dihydrochloride, NEt3, EtOH, reflux; b) see 
Ref. 23 and 24. 
 
The synthesis of the tricyclic derivatives 29-31 and 35-37 is shown in Scheme 6. The 
chromeno[4,3-c]pyrazol-4-ones featuring a benzyl group at position 3, combined with a methyl and 
a benzyl residue at position 1 (29 and 30) [25] and 2 (35 and 36) [25], were obtained from 4-
hydroxy-3-phenacetyl-chromen-2-one (46). The chromeno[4,3-c]pyrazol-4-one derivatives 31 and 
37, lacking a substituent at position 3 and bearing a phenyl group at position 1 or 2, were prepared 
starting from 4-chloro-2-oxo-2H-chromene-3-carbaldehyde 47 [26] which was transformed into the 
corresponding 3-phenylhydrazone 48 [26]. This compound was cyclized by heating in pyridine and 
a catalytic amount of piperidine to provide the 1-phenyl regioisomer 31 [26]. To obtain the 2-phenyl 
regioisomer 37 we employed different conditions from those described [27] as they afforded a 
mixture of the two isomer 31 and 37. In our hands, the intermediate 47 was reacted with an 
equimolar amount of phenylhydrazine in refluxing glacial acetic acid and compound 37 was 
isolated as the sole isomer in good yields.  
The synthesis of the 3,6-dimethylpyrano[4,3-c]pyrazole derivatives 38 [28] and 39 [29] was 














Scheme 6. Reagents and conditions: a) see Ref. 25; b) PhNHNH2.HCl, H2O/AcOH, MeOH, 60 °C; 
c) piperidine, pyridine, 100 °C; d) PhNHNH2, glacial AcOH reflux. 
 
2.2.CA inhibitory activity 
All the synthesized derivatives 1-39 were tested to determine their efficacy against the targeted 
hCAs IX and XII and also toward the hCAs I and II, which are physiologically relevant cytosolic 
isoforms, highly expressed throughout the human body, thus responsible for the side effects of 
nonselective hCA inhibitors. 
The inhibition data of the synthesized compounds at hCAs are reported in Tables 1-3, together with 
those of acetazolamide (AZA) and coumarin, as reference inhibitors. The obtained results indicate 
that enhancement of molecular complexity of the coumarin scaffold ameliorated the potency and 
selectivity toward the targeted hCAs, thus confirming the concept that a more complex ligand can 
present better complementarity for a specific target. None of the tested derivatives was able to 
inhibit the off-target hCAs I and II, some compounds (13, 14, 19, 21, 25, 31, 33, 37 and 39) were 
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potent (Ki < 41 nM) and selective against the hCA IX, and some (6, 11 and 17) were dually potent 
hCAs IX and XII inhibitors (Ki= 5.6-9.6 nM). 
 
Table 1. Inhibition data of the 3-acetyl-2H-chromen-2-one derivatives 1-10 and Acetazolamide 
(AZA) and coumarin, as reference compounds, against hCA I, II, IX and XII isoforms, as 






























Concerning the first set of inhibitors, i.e. the 3-acetylchromen-2-one derivatives 1-10 (Table 1), 
introduction of the acetyl group at the 3-position of coumarin resulted in a strong increase of 
potency at the hCAs IX and XII, compound 1 being active in the nanomolar range (Ki= 151.8 and 
7.8 nM, respectively) against the two isoforms. Due to this encouraging result, further modifications 
were carried out on derivative 1, such as introduction on the fused benzo ring of small substituents 
   Ki (nM)
a
 
 R4 X hCAI hCAII hCAIX hCAXII 
1 H H >10000 >10000 151.8 7.8 
2 H 6-NO2 >10000 >10000 44.9 695.2 
3 H 7-Cl  >10000 >10000 809.4 4529.4 
4 H 6-NO2-7-Cl >10000 >10000 561.2 6400.0 
5 OH H >10000 >10000 35.9 453.5 
6 OH 6-Br >10000 >10000 8.2 5.6 
7 OH 6-NO2 >10000 >10000 44.2 357.1 
8 OMe H >10000 >10000 28.4 673.5 
9 OMe 6-Br >10000 >10000 90.7 706.1 
10 OEt 6-Br >10000 >10000 46.4 737.2 
Coumarin
b
 31000 92000 >500000 >500000 
AZA 250 12.1 25.4 5.6 
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(6-NO2, 7-Cl or both) which, to the best of our knowledge, have been never probed on coumarin 
derivatives designed as hCA inhibitors. Derivatives obtained in this way (2-4) showed lower 
potencies, compared to the lead 1, in particular against the hCA XII isoform. The only exception 
was the 6-nitro derivative 2 being about three-fold more active than 1 against the hCA IX. 
Introduction of a hydroxy group at position 4 of derivatives 1 and 2, to give 5 and 7, elicited 
different effects. Compound 5 was more effective than the parent 1 at the hCA IX (Ki= 35.9 nM) 
and significantly less potent at the hCA XII (Ki= 453.5 nM). In contrast, derivative 7 was as active 
as the parent compound 2. However, compounds 5 and 7 are equally potent against each hCA of 
interest. Introduction of the lipophilic and bulky bromine atom at position 6 of compound 5 turned 
out to be profitable, compound 6 being one of the most potent dual inhibitors of hCAs IX and XII 
among the herein reported derivatives. The effect of 4-hydroxy alkylation carried out on compounds 
5 and 6 is difficult to explain as it afforded opposite results (compounds 8-10). Methylation of the 
4-hydroxy group of 5 left the inhibition profile unchanged (see derivative 8) while the same 
modification on derivative 6 worsened activity about 10-fold against the hCA IX and more 
drastically against the hCA XII (see derivative 9). Transformation of the 4-methoxy derivative 9 
into its superior homologue 4-ethoxy derivative 10 slightly enhanced the hCA IX potency. 
In the second step of the work, we decided to merge a pyrazole nucleus with the bicyclic 3-
acetylchromen-2-one 1 to verify whether the added ring, and other structural elements on it, could 
enhance affinity and selectivity for the targets. First, the 1-phenyl-3-methylchromeno[4,3-c]pyrazol-
4-one 11 was synthesized and tested (Table 2). Compound 11 behaved as a balanced dual inhibitor 
of hCAs IX and XII, endowed with low nanomolar activity (Ki= 9.6 and 5.8 nM), and was more 
potent at the former isoform than the parent derivative 1. These results indicate that compound 11 
possesses a better structural complementarity for the hCA IX, thus suggesting that the fused 
pyrazole nucleus and the lipophilic area represented by the 1-phenyl ring reinforce the interaction 




Table 2. Inhibition data of derivatives 11-27 and Acetazolamide (AZA), as a reference compound, 








Mean from three different assays, and errors were within 10% of the reported values. 
 
To preliminarily investigate the structure-affinity relationships (SAR) in this new class of hCA 
inhibitors, small substituents with different lipophilic and electronic properties (Cl, OMe, Me, 
COOH) were introduced on the 1-phenyl ring (derivatives 12-16). Only the carboxylic residue, both 
   Ki (nM)
a
 
 R X hCAI hCAII hCAIX hCAXII 
11 H H >10000 >10000  9.6 5.8 
12 4-Cl H >10000 >10000 402.8 >10000 
13 4-Me H >10000 >10000 22.2 >10000 
14 4-OMe H >10000 >10000 40.2 >10000 
15 2-COOH H >10000 >10000 76.8 27.3 
16 4-COOH H >10000 >10000 1960.4 24.7 
17 H 8-Br >10000 >10000 8.5 7.1 
18 H 7-Cl  >10000 >10000 57.9 818.7 
19 H 8-NO2 >10000 >10000 27.1 >10000 
20 H 7-Cl, 8-NO2 >10000 >10000 801.2 6062.5 
21 H 8-NH2 >10000 >10000 34.5 >10000 
22 H 8-NHMe >10000 >10000 51.3 737.2 
23 H 8-N(Me)2 >10000 >10000 59.4 359.8 
24 H 8-NHCOMe >10000 >10000 26.8 646.5 
25 H 8-NHCOPh >10000 >10000 15.3 >10000 
26 H 8-NHCONHPh >10000 >10000 77.9 583.2 
27 H 8-NHCH2Ph >10000 >10000 37.8 359.8 
AZA 250 12.1 25.4 5.6 
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at the ortho (15) and para (16) position, afforded potent hCA XII inhibitors (Ki= 27.3 and 24.7 nM, 
respectively). The ortho-isomer 15 also showed quite good activity against the hCA IX. The other 
substituents yielded to hCA IX selective compounds (12-14) since they significantly reduced hCA 
XII inhibition. The 4-methyl- and 4-methoxy-substituted derivatives 13 and 14 are noteworthy, 
showing Ki values in the low nanomolar range (22.2 and 40.2 nM). 
In the second set of tricyclic derivatives (17-20), structural modifications were carried out on the 
fused benzo ring where the same substituents probed on coumarins 1-10 were evaluated. The Ki 
values obtained for 17-20 are overall better than those of the relative bicyclic compounds and the 
observed SARs are similar. In detail, the 8-bromo derivative 17 stands out as one of the best dual 
hCAs IX and XII inhibitors (Ki= 8.5 and 7.1 nM) among those reported here. Also the 8-nitro 
derivative 19 is worth noting, being one of the most potent and selective inhibitors at the hCA IX 
isoform (Ki= 27.1 nM) of those investigated in this work. The 7-chlorine atom (compound 18) 
resulted in a nanomolar potency at the hCA IX (Ki= 57 nM) and a significantly reduced inhibition 
of the hCA XII. The 7-chloro-8-nitro substitution made compound 20 scarcely active at both the 
targeted hCA isoforms. Reduction of the 8-nitro derivative 19 gave the 8-amino derivative 21 
which, similarly to 19, behaves as a selective hCA IX inhibitor endowed with nanomolar potency 
(Ki= 34.5 nM). 
The 8-amino group of 21 was exploited for subsequent derivatizations. Its linkage to groups with 
different steric, lipophilic and electronic properties, such as methyl (22 and 23), acetyl (24), 
phenylcarbamoyl (26) or benzyl (27) showed little effect on the potency against the hCA IX, the 
obtained compounds being as active as 21 (Ki= 37.8-77.9 nM). These 8-amino-modified derivatives 
also showed some ability to inhibit the hCA XII (Ki= 359.9-737.2 nM). Instead, the presence of a 
benzoyl moiety on the 8-amino group (25) afforded the most potent (Ki= 15.3 nM) and selective 




Table 3. Inhibition data of  derivatives 28-39 and Acetazolamide (AZA), as a reference compound, 













Mean from three different assays, and errors were within 10% of the reported values. 
 
Compounds 28-31 (Table 3) ensued from the chromeno[4,3-c]pyrazol-4-one 11 whose 1-phenyl and 
3-methyl substituents were replaced by a benzyl, a methyl or a hydrogen atom to evaluate the steric 
and lipophilic requirements of the molecule in proximity of the two positions. None of these 
modifications ameliorated the inhibitory profile of the lead. In fact, the presence of a benzyl 
pendant at position 1 (28) caused a drop of potency at both hCAs of interest. Compound 29, more 
    Ki (nM)
a
 
 R R3 X hCAI hCAII hCAIX hCAXII 
28 C6H4-CH2 Me - >10000 >10000 371.1 731.9 
29 C6H4-CH2 C6H4-CH2 - >10000 >10000 31.5 818.7 
30 Me C6H4-CH2 - >10000 >10000 19.7 342.9 
31 C6H5 H - >10000 >10000 30.1 >10000 
32 C6H5 Me H >10000 >10000 38.1 593.2 
33 C6H5 Me Br >10000 >10000 25.2 >10000 
34 C6H5 Me NO2 >10000 >10000 35.8 359.8 
35 C6H4-CH2 C6H4-CH2 H >10000 >10000 289.7 671.9 
36 Me C6H4-CH2 H >10000 >10000 555.2 33.3 
37 C6H5 H H >10000 >10000 37.6 >10000 
38 - - - >10000 >10000 26.6 517.7 
39 - - - >10000 >10000 41.4 >10000 
AZA 250 12.1 25.4 5.6 
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hindered than 28 since it features a benzyl group at both the 1- and 2-positions, showed a restored 
activity at the hCA IX, being active at low nanomolar concentration (Ki= 31.5 nM). A comparable 
inhibitory profile was obtained when the 1-benzyl moiety of 29 was replaced with the less lipophilic 
methyl group to give compound 30. An interesting result, although difficult to explain, was found 
for compound 31, where a hydrogen atom was present at position 3 in the place of the 3-methyl 
group of the potent dual hCA IX/XII inhibitor 11. This small change made compound 31 inactive at 
the hCA XII isoform while it preserved activity against the hCA IX (Ki= 30.1 nM), thus suggesting 
that the methyl substituent of 11, although being a small group, plays a crucial role for interaction 
with the hCA XII enzymatic site.  
The set of derivatives 32-37 (Table 3) was synthesized to evaluate the effect of moving the 
lipophilic area (Ph, CH2Ph, Me) from the 1- to the 2-position of the best inhibitors identified in the 
meanwhile, i.e. compounds 11, 17, 19, 29-31. This modification, although it significantly changed 
the shape of the molecules, gave rise to some potent hCA IX inhibitors (32-34, 37). The compounds 
showed in fact nanomolar activities (Ki= 25.2-38.1 nM) even if they were in general less active than 
the 1-substituted counterparts (11, 17, 19 and 31) on both the isoforms. It is worth noting that the 8-
bromo-derivative 33 was hCA IX selective while its regioisomer 17 was active on both the targeted 
enzymes. Derivatives 35 and 36, featuring a benzyl moiety at position 3, displayed scarce potencies 
on the hCAs of interest, with the exception of the hCA XII inhibitor activity of 36 in the low 
nanomolar range.  
Finally, the fused benzo ring of the 1-phenyl- and 2-phenyl- substituted chromenopyrazole 
derivatives 11 and 32 was replaced with a methyl residue to give the pyrano[4,3-c]pyrazol-4-one 
derivatives 38 and 39. Both compounds maintained the capability of blocking the hCA IX with high 
potency (Ki= 26.6 and 41.4 nM) while they were less active against the hCA XII. As observed in 
the tricyclic series, the 1-phenyl derivative 38 showed a higher potency with respect to the 2-




2.3. Cell toxicity assays  
Some selected compounds, belonging to the 3-acetylcoumarin set (6) and to the chromeno[4,3-
c]pyrazol-4-one (11, 13, 19, 21, 25, 31) and pyrano[4,3-c]pyrazol-4-one (39) series, were chosen 
among those possessing the best inhibitory profile and tested (30 – 300 µM) to evaluate their effects 
on viability of human colon cancer HT-29 cells. Tests were performed over time (16 and 48 h) 
under normoxic and hypoxic conditions. The efficacy of the compounds is summarized in Figures 2 
(6, 11, 13 and 19) and 3 (21, 25, 31 and 39) in comparison to untreated control (100% viability).  
As a general trend, after 16 h incubation, the tested derivatives significantly inhibited cell viability 
in normoxic conditions while most of them did not have any effect in hypoxia. A similar behavior 
was also observed after 48 h incubation, with the exception of compounds 19, 31 and 39 which 
turned out to be more active under hypoxic conditions.  
Analyzing the results in greater detail, in normoxic conditions, compounds 6, 13, 21 and 25 showed 
a concentration- and time-dependent efficacy in reducing cancer cell viability. It was not possible to 
test 6 and 13 at the higher concentration (300 M) for their low solubility in the assay medium. 
Derivatives 6 and 25 (100 μM, 48 h) reduced the number of living cells up to about 35 and 50%, 
respectively. Compounds 11, 19 and 39 showed the peculiarity of a dramatic concentration-
dependent effect after 16 h incubation. The lower activity after 48 h could be related to a reduced 
stability of the solutions rather than an intrinsic variation of efficacy. In hypoxic conditions, the 
longer incubation time favors activity: after 48 h compounds 6, 11, 19, 21, 31 and 39 were 
significantly effective. In particular, the 2-phenylchromeno-pyrazol-4-one 31 (30 μM, 48 h, 
hypoxia) showed the best profile reducing cell viability up to 70%. 
Finally, a long incubation time (72 h) was experimented. Only the activities of the most interesting 
derivatives (selected by solution stability and effectiveness) are reported in Figure 4. Compound 6 
maintained efficacy as shown also for shorter times. With regard to compounds 21, 25 and 39, a 
longer time of incubation promoted activity in hypoxic conditions. In particular, compound 25 (100 
μM) decreased cancer cell viability to 40%. 
18 
 
It is difficult to explain why some compounds showed cytotoxic effects not only in hypoxia (when 
hCA IX is overexpressed) but also in normoxia, when the enzyme is not present in these cells. Thus, 
it is possible that, besides interfering with the hCA IX/XII activity in hypoxia, they may exert their 
cytotoxic effects through other mechanisms of action, involving pathways in normoxia. A similar 
behavior was observed also for other hCA inhibitors, such as sulfocoumarins [13], 3-









/well) were treated with compounds 6 (A), 11 (B), 13 (C) and 19 (D) (0 - 
300 μM). Incubation was allowed for 16 or 48 h in normoxic (20% O2) and hypoxic conditions 
(0.1% O2). Cell viability was measured by MTT assay. The control condition was arbitrarily set as 
100% and values are expressed as the mean ± SEM of three experiments. *P<0.05, **P<0.01 and 









/well) were treated with compounds 21 (E), 25 (F), 31 (G), and 39 (H) (0 - 
300 μM). Incubation was allowed for 16 or 48 h in normoxic (20% O2) and hypoxic conditions 
(0.1% O2). Cell viability was measured by MTT assay. The control condition was arbitrarily set as 
100% and values are expressed as the mean ± SEM of three experiments. *P<0.05, **P<0.01 and 













/well) were treated with compounds 6 (A), 21 (B), 25 (C), and 39 (D) (0 - 
300 μM). Incubation was allowed for 72 h in normoxic (20% O2) and hypoxic conditions (0.1% 
O2). Cell viability was measured by MTT assay. The control condition was arbitrarily set as 100% 
and values are expressed as the mean ± SEM of three experiments. *P<0.05, **P<0.01 and 







In this work, different structural modifications were carried out on the coumarin scaffold leading to 
a set of 3-acetyl-coumarin derivatives and, more interestingly, to new classes of inhibitors of the 
tumor-associated hCAs IX and XII: the chromeno[4,3-c]pyrazol-4-ones and the pyrano[4,3-
c]pyrazol-4-ones. Several synthesized derivatives showed Ki values in the low nanomolar range, 
being either selective against the hCA IX or dual inhibitors on both the hCA isoforms of interest. 
None of the compounds was effective in inhibiting the cytosolic enzymes hCAs I and II. Some 
inhibitors proved to be active as antiproliferative agents on HT-29 colon cancer cell lines, both in 
normoxic and hypoxic conditions. This finding led us to hypothesize for these derivatives more than 
one mechanism of action, involving hCAs IX and XII in hypoxia and other not identified target(s) 
in normoxia. 
 
4. Experimental section 
4.1 Chemistry.  
All the commercially available reagents and solvents were used as purchased from Sigma-Aldrich 
and Alfa Aesar (Italy) without further purification. Analytical silica gel plates (Merck F254) and 
silica gel 60 (Merck, 70-230 mesh) were used for analytical TLC and for column chromatography, 
respectively. All melting points were determined on a Gallenkamp melting point apparatus and are 
uncorrected. Compounds were named following IUPAC rules as applied by ChemDrawUtra 9.0. 
Elemental analyses were performed with a Flash E1112 Thermofinnigan elemental analyzer for C, 
H, N and the results were within ± 0.4% of the theoretical values. All final compounds revealed 
purity not less than 95%. The IR spectra were recorded with a Perkin-Elmer Spectrum RX I 
spectrometer in Nujol mulls and are expressed in cm
-1
. NMR spectra were recorded on a Bruker 
Avance 400 spectrometer (400 MHz for 
1
H NMR and 100 MHz for 
13
C NMR). The chemical shifts 
are reported in δ (ppm) and are relative to the central peak of the solvent which was CDCl3 or 
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DMSOd6. The following abbreviations are used: s= singlet, d= doublet, t= triplet, q= quartet, m= 
multiplet, br= broad and ar= aromatic protons.  
Compounds 2 [22], 5 [23], 6 [24], 11-14 [23], 17 [24], 29-30 [25], 32 [23], 33 and 34 [24], 35 and 
36 [25], 38 [28], 39 [29] were prepared according previously reported procedures. 
 
4.1.1. 3-Acetyl-7-chloro-2H-chromen-2-one (3) 
A mixture of 4-chloro-2-hydroxybenzaldeyde (8.98 mmol), ethyl acetoacetate (22.4 mmol) and 
catalytic amount of piperidine (0.22 mmol) was stirred at room temperature for 10 min, then it was 
diluted with EtOH (10 mL). The solid which precipitated was collected by filtration and 
recrystallized. Yield 90%; mp 170-171 °C (2-Methoxyethanol); 
1
H NMR (CDCl3):  2.74 (s, 3H, 
CH3), 8.34 (dd, 1H, H-6, J = 8.4, 1.9 Hz), 7.35 (d, 1H, H-8, J = 1.7 Hz), 8.01 (d, 1H, H-5, J = 8.3 
Hz), 8.49 (s, 1H, H-4). 
13
C NMR (DMSO-d6): 30.92 (CH3), 117.27, 118.18, 125.33, 126.26, 
133.02, 139.74, 147.25, 155.92, 158.88, 195.80. IR: 1678, 1741. Anal. C11H7ClO3 (C, H, N). 
 
4.1.2. 3-Acetyl-7-chloro-6-nitro-2H-chromen-2-one (4) 
3-Acetyl-7-chloro-2H-chromen-2-one 3 (2.25 mmol) was added portionwise to cooled HNO3 (90 
%, -10 °C). When the addition was complete, the mixture was stirred for about 2h at -10 °C, then 
the solution was poured onto ice (about 100 g) and the solid collected, washed with abundant water 
(about 100 mL), dried and recrystallized. Yield 88%; mp 210-212 °C (EtOH); 
1
H NMR (CDCl3):  
2.75 (s, 3H, CH3), 7.58 (s, 1H, H-8), 8.31 (s, 1H, ar), 8.49 (s, 1H, ar). 
13
C NMR (DMSO-d6): 
30.36 (CH3), 118.16, 120.01, 126.67, 128.61, 130.97, 143.92, 145.33, 156.66, 157.58, 194.95. IR: 
1686, 1737. Anal. C11H6ClNO5 (C, H, N). 
 
4.1.3. 3-Acetyl-4-hydroxy-6-nitro-2H-chromen-2-one (7) 
3-Acetyl-4-hydroxy-2H-chromen-2-one 5 (2.45 mmol) [23] was portionwise added to a cooled 
solution (0 °C) of KNO3 (2.45 mmol) in H2SO4 (10 mL). When the addition was complete, the 
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mixture was stirred for about 1h at 0 °C, then the solution was poured onto ice (about 50 g) and the 
solid collected, washed with abundant water (about 50 mL), dried and recrystallized. Yield 98%; 
mp 230-231 °C (EtOH); 
1
H NMR (CDCl3):  2.83 (s, 3H, CH3), 7.48 (d, 1H, H-8, J = 9.0 Hz), 8.55 
(dd, 1H, H-7, J = 9.2, 2.5 Hz), 8.98 (d, 1H, H-5, J = 2.2 Hz). 
 
4.1.4. General procedure for the synthesis of 3-acetil-4-metossi-2H-chromen-2-one derivatives 
8, 9 
A mixture of 3-acetil-4-hydroxy-2H-chromen-2-one derivatives 5 [23] or 6 [24] (0.98 mmol), 
K2CO3 (2.94 mmol) and dimethylsulfate (1.17 mmol) in anhydrous acetone (3 mL), was microwave 
irradiated at 125 °C for 6 min. The suspension was poured onto iced water (50 mL) and neutralized 
with 10% HCl solution. The mixture was extracted with Et2O (30 mL x 3), then the organic phase 
was washed with a NaHCO3 saturated solution (50 mL) and brine (50 mL). The dried (Na2SO4) 
organic phase was evaporated at reduced pressure to give an oil residue which solidified upon 
treatment with Et2O (2-3 mL). The crude compound was purified by column chromatography 
(cyclohexane/EtOAc 6:4). 
4.1.4.1. 3-Acetyl-4-methoxy-2H-chromen-2-one (8). Yield 74%; mp 81-83 °C (MeOH); 1H NMR 
(CDCl3): 2.72 (s, 3H, CH3), 4.02 (s, 3H, OCH3), 7.30-7.34 (m, 2H, ar), 7.61 (t, 1H, ar, J = 7.2 Hz), 
7.91 (d, 1H, H-5, J = 7.9 Hz). IR 1699, 1713. Anal. C12H10O4 (C, H, N). 
4.1.4.2. 3-Acetyl-6-bromo-4-methoxy-2H-chromen-2-one (9). Yield 70%; mp 147-149 °C 
(MeOH); 
1
H NMR (CDCl3): 2.71 (s, 3H, CH3), 4.01 (s, 3H, OCH3), 7.22 (d, 1H, H-8, J = 7.8 Hz), 
7.69 (dd, 1H, H-7, J = 8.4, 2.2 Hz), 8.03 (d, 1H, H-5, J =2.2 Hz). 
13
C NMR (DMSO-d6): 32.95 
(CH3), 62.67 (OCH3), 110.63, 117.50, 118.96, 119.80, 127.40, 136.82, 151.93, 161.22, 162.02, 
200.74. IR: 1693, 1710. Anal. C12H9ClBrO4 (C, H, N). 
 
4.1.5. 3-Acetyl-4-ethoxy-6-bromo-2H-chromen-2-one (10)  
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A suspension of the 4-methoxy-2H-chromen-2-one derivative 9 (0.3 mmol) in absolute EtOH (25 
mL) was refluxed for 6 h. The insoluble solid was collected by filtration and recrystallized. Yield 
75%; mp 116-118 °C (EtOH); 
1
H NMR (CDCl3):  1.52 (t, 3H, CH3, J = 6.9 Hz), 2.69 (s, 3H, CH3), 
4.15 (q, 2H, CH2, J = 6.9 Hz), 7.22 (d, 1H, H-8, J = 8.8 Hz), 7.68 (dd, 1H, H-7, J = 8.4, 2.2 Hz), 8.01 
(d, 1H, H-5, J = 2.2 Hz). 
13
C NMR (CDCl3): 15.36 (CH3), 32.16 (CH3), 70.97 (CH2), 117.21, 
118.37, 127.05, 135.95, 147.34, 149.04, 151.42, 153.07, 160.81, 161.63. IR: 1699, 1712. Anal. 
C13H11ClBrO4 (C, H, N). 
 
4.1.6. 2-(2-(1-(2-Oxo-2H-chromen-3-yl)ethylidene)hydrazinyl)benzoic acid (40) 
A mixture of the suitable 2-hydrazinobenzoic acid hydrochloride [30] (2.58 mmol) and 
triethylamine (2.58 mmol) in EtOH (30 mL) was stirred at reflux for 5-10 min, then the 3-acetyl-4-
hydroxy-2H-chromen-2-one 5 (1.29 mmol) was added and the mixture was heated for an additional 
30 min. After cooling at room temperature, the solid was collected, washed with water (about 10-20 
mL) and recrystallized. Yield 92%; mp 245-246 °C (EtOH); 
1
H NMR (DMSOd6): 2.69s, 3H, 
CH3), 6.97 (t, 1H, ar, J = 7.6 Hz), 7.02 (d, 1H, ar, J = 8.5 Hz), (m, 2H, ar), 7.57 (t, 1H, 
ar, J = 8.5 Hz), 7.66 (t, 1H, J = 7.8 Hz), d, 1H, ar, J = 7.8 Hz), 8.00 (d, 1H, ar, J = 7.6 
Hz)10.28 (s, 1H, NH),(br s, 1H, OH) Anal. C18H14N2O5 (C, H, N). 
 
4.1.7. 2-(3-Methyl-4-oxochromeno[4,3-c]pyrazol-1(4H)yl)benzoic acid (15) 
A mixture of arylhydrazone 40 (2.96 mmol) and a catalytic amount of p-toluensulfonic acid in 
anhydrous xylene (50 mL) was refluxed for about 1h, while water was distilled off using a Dean-
Stark apparatus. The mixture was concentrated by removing about half of the solvent, then cooled 
at rt and filtered to remove the tarry residue. After addition of ligroin to the filtrate, a solid was 
obtained which was collected by filtration and recrystallized. Yield 48%; mp > 300 °C (EtOH). 
1
H 
NMR (DMSOd6): sCH3), 6.79 (d, 1H, ar, J = 7.3 Hz), 7.17 (t, 1H, ar, J = 8.0 Hz), 7.52-
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7.57 (m, 2H, ar), 7.77 (d, 1H, ar, J = 7.6 Hz), 7.83-7.89 (m, 2H, ar), 8.15 (d, 1H, ar, J = 7.4 Hz). 
13
C 
NMR (DMSOd6): 13.49 (CH3), 105.93, 112.55, 118.64, 122.69, 125.38, 130.33, 130.57; 132.00, 
132.31, 132.45, 134.56, 138.97, 143.31, 149.94, 153.48, 158.02, 166.50. IR 1713, 1747. Anal. 
C18H12N2O4 (C, H, N). 
 
4.1.8 General procedure for the synthesis of arylhydrazones of 3-acetyl-2H-chromen-2-ones 41-
44  
A mixture of the suitable arylhydrazine (1.42 mmol) and 3-acetyl-derivatives 1-4 (1.29 mmol) in 
EtOH (5 mL) was heated at reflux for about 1-2 h. After cooling at room temperature, the solid was 
collected and recrystallized. 
4.1.8.1. 4-(2-(1-(2-Oxo-2H-chromen-3-yl)ethylidene)hydrazinyl)benzoic acid (41) Yield 87%; mp 
227-229 °C (2-methoxyethanol); 
1
H NMR (DMSOd6): 2.26 (s, 3H, CH3), 7.29 (d, 2H, ar, J = 8.8 
Hz), 7.42 (t, 1H, ar, J = 8.2 Hz), 7.62 (t, 1H, ar, J = 7.2 Hz), 7.82 (d, 2H, ar, J = 8.8 Hz), 7.86 (d, 
1H, ar, J = 6.7 Hz), 8.25 (s, 1H, H-4), 9.89 (s, 1H, NH), 12.35 (br s, 1H, OH). IR 1682, 1720, 3290. 
Anal. C18H14N2O4 (C, H, N).  
4.1.8.2. 7-Cloro-3-(1-(2-phenyldrazono)ethyl)-2H-chromen-2-one (42). Yield 58%; mp 153-155 °C 
(EtOH); 
1
H NMR (CDCl3): 2.31 (s, 3H, CH3), 6.94 (t, 1H, ar, J = 7.2 Hz), 7.18 (d, 2H, ar, J = 7.6 
Hz), 7.31 (m, 3H, ar), 7.38 (d, 1H, H-8, J = 1.6 Hz), 7.52 (d, 1H, H-5, J = 8.4 Hz), 7.58 (s, 1H, NH), 
8.05 (s, 1H, H-4). IR: 1720, 3331. Anal. C17H13ClN2O2 (C, H, N). 
4.1.8.3. 3-(1-(2-Phenyldrazono)ethyl)-8-nitro-2H-chromen-2-one (43). Yield 52%; mp 204-206 °C 
(EtOH); 
1
H NMR (CDCl3): 2.33 (s, 3H, CH3), 6.97 (t, 1H, ar, J = 7.6 Hz), 7.20 (d, 2H, ar, J = 7.6 
Hz), 7.34 (t, 2H, ar, J = 7.6 Hz), 7.48 (d, 1H, H-8, J = 9.2 Hz), 7.68 (s, 1H, NH), 8.16 (s, 1H, H-4), 
8.39 (dd, 1H, H-7, J = 8.8, 2.8 Hz), 8.53 (d, 1H, H-5, J = 2.4 Hz). IR: 1340, 1516, 1726, 3328. Anal. 
C17H13N3O4 (C, H, N). 
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4.1.8.4. 7-Chloro-3-(1-(2-phenyldrazono)ethyl)-8-nitro-2H-chromen-2-one (44). Yield 70%; mp 
220-221 °C (2-Methoxyethanol); 
1
H NMR (CDCl3): 2.32 (s, 3H, CH3), 6.97 (t, 1H, ar, J = 7.6 
Hz), 7.18 (d, 2H, ar, J = 8.0 Hz), 7.33 (t, 2H, ar, J = 8.0 Hz), 7.52 (s, 1H, H-8), 7.69 (s, 1H, NH), 
8.08 (s, 1H, H-5), 8.23 (s, 1H, H-4). IR: 1355, 1525, 1741, 3342. Anal. C17H12ClN3O4 (C, H, N). 
 
4.1.9. General procedure for the synthesis of 1-aryl-3-methylchromeno[4,3-c]pyrazol-4-(1H)-one 
derivatives 16, 18-20 
A mixture of arylhydrazones (1.55 mmol), Cu(AcO)2·monohydrate and CuSO4·pentahydrate, 
respectively 20% and 10% w/w with respect to the hydrazone, in EtOH (8 mL) was heated at reflux 
for 6-24 h. After cooling, the insoluble solid was collected by filtration, washed with abundant 
water (about 20-30 mL), dried, and purified by column chromatography (CH2Cl2/MeCN 9.8:0.2). 
To obtain compound 16, the crude solid was suspended in HCl 6N and the mixture was stirred at rt 
for about 30 min, then collected, washed with water, dried, and recrystallized. 
4.1.9.1. 4-(3-Methyl-4-oxochromeno[4,3-c]pyrazol-1(4H)yl)benzoic acid (16). Yield 25%; mp >300 
°C (2-Methoxyethanol) 
1
H NMR (DMSOd6): 2.57 (s, 3H, CH3), 7.08 (d, 1H, ar, J = 7.9 Hz), 7.20 
(t, 1H, ar, J = 7.5 Hz), 7.52 (d, 1H, ar, J = 8.1 Hz), 7.58 (t, 1H, ar, J = 7.8 Hz), 7.80 (d, 2H, ar, J = 
8.0 Hz), 8.20 (d, 2H, ar, J = 8.0 Hz), 13.39 (br s, 1H, COOH). 
13
C NMR (DMSOd6): 13.43 (CH3), 
106.93, 112.22, 118.72, 123.21, 125.34, 128.05, 131.92, 132.55, 133.28, 142.37, 143.35, 150.77, 
153.63, 157.93, 167.37. IR: 1690, 1742. Anal. C18H12N2O4 (C, H, N). 
4.1.9.2. 7-Chloro-3-methyl-1-phenylchromeno[4,3-c]pyrazol-4-(1H)-one (18). Yield 48%; mp 193-
195 °C (EtOH); 
1
H NMR (CDCl3): 2.71 (s, 3H, CH3), 7.04 (br s, 2H, H-6 + H-8), 7.46 (s, 1H, H-
9), 7.54-7.56 (m, 2H, ar), 7.63-7.65 (m, 3H, ar). 
13
C NMR (CDCl3): 12.84 (CH3), 110.48, 118.31, 
118.86, 123.28, 124.45, 126.80, 128.73, 130.06, 130.39, 136.91, 139.16, 141.08, 151.02, 153.61. 
IR: 1747. Anal. C17H11ClN2O2 (C, H, N). 
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4.1.9.3. 3-Methyl-8-nitro-1-phenylchromeno[4,3-c]pyrazol-4-(1H)-one (19). Yield 80%; mp 241-
242 °C (EtOAc); 
1
H NMR (CDCl3): 2.75 (s, 3H, CH3), 7.55-7.59 (m, 3H, ar), 7.60-7.80 (m, 3H, 
ar), 8.05 (d, 1H, H-9, J = 2.4 Hz), 8.33 (dd, 1H, H-7, J = 9.2, 2.4 Hz).  
4.1.9.4. 7-Chloro-3-methyl-8-nitro-1-phenylchromeno[4,3-c]pyrazol-4-(1H)-one (20). Yield 77%; 
mp 265-267 °C (2-Methoxyethanol); 
1
H NMR (CDCl3): 2.72 (s, 3H, CH3), 7.50-7.60 (m, 2H, ar), 
7.61 (s, 1H, ar), 7.65-7.70 (m, 3H, ar), 7.74 (s, 1H, ar). IR: 1377, 1577, 1768. Anal. C17H10ClN3O4 
(C, H, N).  
 
4.1.10. 8-Amino-3-methyl-1-phenylchromeno[4,3-c]pyrazol-4-(1H)-one (21).  
Pd/C 10% (10% w/w with respect to the nitro derivative) was added to a solution of the nitro 
derivative 19 (3.58 mmol) in DMF (5 mL). The mixture was hydrogenated in a Parr apparatus at 35 
psi for 14 h. The catalyst was filtered off, and the clear solution was diluted with water (about 50 
mL) and the obtained solid was collected by filtration, washed with water and purified by column 
chromatography (eluent cyclohexane/EtOAc 6:4). Yield 77%; mp 201-204 °C (EtOH); 
1
H NMR 
(CDCl3): 2.73 (s, 3H, CH3), 3.52 (br s, 2H, NH2), 6.33 (d, 1H, H-9, J = 2.4 Hz), 6.81 (dd, 1H, ar, J 
= 8.8, 2.4 Hz), 7.22 (d, 1H, ar, J = 8.8 Hz), 7.50-7.70 (m, 5H, ar). 
13
C NMR (CDCl3):  12.92 
(CH3), 106.69, 106.86, 112.18, 118.18, 118.88, 127.02, 129.76, 130.07, 139.48, 141.70, 142.38, 
146.67, 150.79, 158.39. IR: 1726, 3228-3342. Anal. C17H13N3O2 (C, H, N).  
 
4.1.11. 3-Methyl-8-methylamino-1-phenylchromeno[4,3-c]pyrazol-4-(1H)-one (22) and 8-
dimethylamino-3-methyl-1-phenylchromeno[4,3-c]pyrazol-4-(1H)-one (23) 
A mixture of the 8-amino derivative 21 (1.56 mmol), anhydrous K2CO3 (2.34 mmol) and methyl 
iodide (15.58 mmol) in anhydrous acetonitrile (10 mL), was stirred at rt for 22 h, then it was diluted 
with water (15 mL) and extracted with CH2Cl2 (33 mL x 3). The organic phase was anhydrified 
(Na2SO4) and the solvent was evaporated at reduced pressure to yield a solid which was treated with 
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a few Et2O (3-5 mL) and collected by filtration. The crude solid was a mixture of compounds 22 
and 23 (ratio 1:2 from 
1
H-NMR spectrum) which were separated by column chromatography 
(cyclohexane/EtOAc 1:1).  
4.1.11.1. Compound 22. Yield 10%; mp 220-222 °C (2-Propanol); 
1
H NMR (CDCl3): 2.51 (s, 3H, 
CH3), 2.71 (s, 3H, NCH3), 3.61 (br s, 1H, NH), 6.18 (d, 1H, H-9, J = 2.4 Hz), 6.74 (dd, 1H, H-7, J = 
9.2, 2.4 Hz), 7.26 (s, 1H, H-6), 7.50-7.70 (m, 5H, ar). 
13
C NMR (CDCl3): 12.97 (CH3), 31.05 
(CH3), 104.06, 112.49, 117.94, 118.91, 127.17, 129.75, 130.10, 139.57, 141.88, 146.60, 151.01, 
156.19, 158.55, 177.25. IR: 1732, 3427. Anal. C18H15N3O2 (C, H, N). 
4.1.11.2. Compound 23. Yield 20%; mp 189-191 °C (2-Propanol); 
1
H NMR (CDCl3): 2.68 (s, 6H, 
N(CH3)2), 2.71 (s, 3H, CH3), 6.30 (d, 1H, H-9, J = 2.9 Hz), 6.87 (dd, 1H, H-7, J = 9.2, 2.9 Hz), 7.31 
(d, 1H, H-6, J = 9.2 Hz), 7.50-7.70 (m, 5H, ar). 
13
C NMR (CDCl3): 13.03 (CH3), 40.55 (CH3), 
104.62, 106.57, 111.72, 116.44, 118.38, 127.30, 129.60, 130.01, 139.55, 142.17, 145.44, 146.67, 
150.60, 158.54. IR: 1735. Anal. C19H17N3O2 (C, H, N). 
 
4.1.12. General procedure for the synthesis of the 8-acylamino-3-methyl-1-phenylchromeno[4,3-
c]pyrazol-4-(1H)-ones 24 and 25. 
The suitable acyl chloride (0.56 mmol) was added to a solution of the 8-amino derivative 21 (0.47 
mmol) and triethylamine (0.56 mmol) in anhydrous CH2Cl2 (10 mL). The mixture was stirred at rt 
for 3 h, then the solvent was evaporated at reduced pressure and the residue was treated with water 
(10 mL). The obtained solid was collected by filtration, washed with abundant water (50 mL) and 
dried. The 8-acetylamino derivative 24 was purified by column chromatography (eluent 
cyclohexane/EtOAc 2:8) while the 8-benzoylamino derivative 25 was recrystallized. 
4.1.12.1. 8-Acetylamino-3-methyl-1-phenylchromeno[4,3-c]pyrazol-4-(1H)-one (24). Yield 65%; 
mp 282-285°C (2-Propanol); 
1
H NMR (CDCl3): 2.11 (s, 3H, COCH3), 2.71 (s, 3H, CH3), 6.99 (br 
s, 1H, NH), 7.40 (br s, 2H, ar), 7.59-7.62 (m, 3H, ar), 7.67-7.80 (m, 3H, ar). 
13
C NMR (DMSO-d6): 
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13.44 (CH3), 24.71 (CH3), 106.62, 112.23, 112.99, 118.85, 123.51, 127.54, 130.88, 130.99, 
136.37, 139.76, 142.17, 149.22, 150.23, 158.10, 169.01. IR: 1716, 1732, 3444. Anal. C19H15N3O3 
(C, H, N). 
4.1.12.2. 8-Benzoylamino-3-methyl-1-phenylchromeno[4,3-c]pyrazol-4-(1H)-one (25). Yield 76%; 
mp 284-286 °C (2-Propanol); 
1
H NMR (CDCl3): 2.73 (s, 3H, CH3), 7.40-7.68 (m, 13H, 12 ar + 
NH), 7.78 (d, 1H, ar, J = 7.3 Hz). 
13
C NMR (DMSO-d6): 12.99 (CH3), 106.15, 111.71, 114.13, 
118.34, 124.61, 127.08, 128.06, 128.84, 130.4, 130.48, 132.09, 135.11, 135.63, 139.27, 141.68, 
149.22, 149.79, 157.63, 165.89. IR: 1710, 1730, 3375. Anal. C24H17N3O3 (C, H, N). 
 
4.1.13. 1-Phenyl-3-(3-methyl-4-oxo-1-phenyl-1,4-dihydrochromeno[4,3-c]pyrazol-8-yl)urea (26).  
A solution of the 8-amino derivative 21 (0.62 mmol) and phenylisocyanate (0.99 mmol) in 
anhydrous THF anidro (10 mL), was heated at reflux for 12 h. The solvent was evaporated at 
reduced pressure and the solid residue was taken up with Et2O (5 mL), collected and recrystallized. 
Yield 90%; mp < 300 °C (2-Methoxyetanol/H2O); 
1
H NMR (DMSO-d6): 2.56 (s, 3H, CH3), 6.96 
(t, 1H, ar, J = 7.2 Hz), 7.20-7.35 (m, 4H, ar), 7.38 (d, 1H, ar, J = 7.6 Hz), 7.45 (d, 1H, ar, J = 8.8 Hz), 
7.55-7.75 (m, 6H, ar), 8.59 (br s, 1H, NH), 8.64 (br s, 1H, NH). 
13
C NMR (DMSO-d6): 12.97 
(CH3), 111.67, 111.89, 118.44, 118.64, 122.37, 122.61, 127.20, 129.24, 130.41, 130.53, 136.28, 
139.35, 139.94, 141.65, 148.18, 149.76, 152.65, 157.67, 166.53. IR: 1689, 1710, 3356, 3394. Anal. 
C24H18N4O3 (C, H, N).  
 
4.1.14. 8-Benzylideneamino-3-methyl-1-phenylchromeno[4,3-c]pyrazol-4-(1H)-one (45).  
A mixture of the 8-amino derivative 21 (0.47 mmol), benzaldehyde (0.56 mmol) and anhydrous 
ZnCl2 (0.56 mmol) in anhydrous THF (10 mL) was heated at reflux for 8 h, under nitrogen 
atmosphere. After cooling at rt, the mixture was diluted with iced water (25 mL) and extracted with 
CH2Cl2 (33 mL x 3). The organic phase was anhydrified (Na2SO4) and the solvent evaporated at 
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reduced pressure to give an oily residue which solidified upon treatment with Et2O (about 2 mL). 
The solid was collected and directly used for the next step. Yield 68%; 
1
H NMR (CDCl3): 2.73 (s, 
3H, CH3), 6.95 (d, 1H, H-9, J = 2.0 Hz), 7.45-7.75 (m, 11 H, ar), 7.80 (d, 1H, H-6, J = 6.8 Hz), 8.19 
(s, 1H, CH=).  
 
4.1.15. 8-Benzylamino-3-methyl-1-phenylchromeno[4,3-c]pyrazol-4-(1H)-one (27).  
NaBH4 (0.59 mmol) was portionwise added to a boiling suspension of the 8-benzylideneamino 
derivative 45 (0.29 mmol) in anhydrous CH3OH (10 mL). After the addition was complete (about 
10 min), the suspension was heated at reflux for an additional 40 min. After cooling at rt, the 
mixture was poured onto ice (about 25 g) and the obtained solid was collected by filtration, washed 
with abundant water (100 mL), collected by filtration and dried. The crude compound was purified 
by column chromatography (eluent CH2Cl2/ acetonitrile 9.8: 0.2). Yield 65%; mp 200-202 °C 
(EtOH); 
1
H NMR (CDCl3): 2.69 (s, 3H, CH3), 3.99 (br s, 3H, CH2 + NH), 6.24 (d, 1H, H-9, J = 
2.4 Hz), 6.78 (dd, 1H, H-7, J = 8.8, 2.4 Hz), 7.14 (d, 1H, H-6), 7.20-7.40 (br s, 5H, ar), 7.45-7.60 
(m, 5H, ar). 
13
C NMR (CDCl3): 12.92 (CH3), 47.84 (CH2), 80.52, 100.00, 103.26, 112.13, 117.60, 
118.82, 127.03, 127.38, 128.64, 129.56, 129.94, 138.37, 139.41, 142.00, 144.05, 146.14, 150.73. 
IR: 1720, 3340. Anal. C24H29N3O2 (C, H, N). 
 
4.1.16. 1-Benzyl-3-methylchromeno[4,3-c]pyrazol-4-(1H)-one (28).  
A mixture of 3-acethyl-4-hydroxychromen-4-one 5 (3.91 mmol), benzylhydrazine dihydrochloride 
(15.64 mmol) and triethylamine (31.28 mmol) in EtOH (30 mL) was heated at reflux for 6 h. Part of 
the solvent (about 20 mL) was evaporated at reduced pressure and the solid which precipitated was 
collected by filtration and purified by column chromatography (eluent CHCl3/CH3OH 9:1). Yield 
45%, mp 169-171 °C (EtOH); 
1
H NMR (CDCl3): 2.69 (s, 3H, CH3), 5.81 (s, 2H, CH2), 7.16-7.49 
(m, 8H, ar), 7.68 (d, 1H, ar, J= 7.9 Hz). Anal. C18H14N2O2 (C, H, N). 
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4.1.17. 1-Phenylchromeno[4,3-c]pyrazol-4-(1H)-one (31). 
A solution of the 3-phenylhydrazone 48 [26] in pyridine (4 ml) and piperidine (0.02 mL) was 
heated at 100 °C for 2 h. After cooling at room temperature, the solution was diluted with H2O (20 
mL) and acidified (2 N HCl) until the formation of a solid which was collected, washed with H2O 
(about 50 mL), dried and purified by column chromatography (eluent cyclohexane/EtOAc, 6:4) and 
recrystallized. Yield 66%, mp 196-197 °C (EtOH); 
1
HNMR (CDCl3): 7.09 (t, 1H, ar, J = 6.8 Hz), 
7.16 (d, 1H, ar, J = 7.6 Hz), 7.45-7.55 (m, 2H, ar), 7.55-7.75 (m, 5H, ar), 8.39 (s, 1H, H-3); 13C 
NMR (DMSO-d6): 13.53 (CH3), 55.40 (CH2), 106.47, 112.24, 118.58, 124.21, 125.49, 127.40, 
128.65, 132.14, 137.04, 141.66, 149.53, 153.40, 157.92. 
 
4.1.18. 2-Phenylchromeno[4,3-c]pyrazol-4-(1H)-one (37). 
A solution of the hydrazone 48 [26] (0.67 mmol) and phenylhydrazine hydrochloride (0.67 mmol) 
in glacial acetic acid (10 mL) was heated under reflux for 10 min. After cooling at room 
temperature, a solid precipitated which was collected by filtration, washed with abundant water (20-
30 mL), and recrystallized. Yield 64%, mp 210-211 °C (EtOH); 
1
HNMR (CDCl3): 7.35-7.65 (m, 
6H, ar), 7.87 (d, 2H, ar, J =7.6 Hz), 7.87 (d, 1H, ar, J = 7.6 Hz), 8.71 (d, 1H, H-3).  
 
4.2. CA inhibition  
An applied photophysics stopped-flow instrument has been used for assaying the hCA catalyzed CO2 
hydration activity [32]. Phenol red (at a concentration of 0.2 mM) has been used as indicator, working 
at the absorbance maximum of 557 nm, with 20 mM Hepes (pH 7.4) as buffer, and 20 mM Na2SO4 
for maintaining constant the ionic strength (this anion is not inhibitory and has a Ki> 200mM against 
these enzymes), following the initial rates of the CA-catalyzed CO2 hydration reaction for a period of 
10–100 s. The CO2 concentrations ranged from 1.7 to 17 mM for the determination of the kinetic 
parameters and inhibition constants. For each measurement three traces of the initial 5–10% of the 
reaction have been used for determining the initial velocity (which was the mean of the three traces), 
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working with 10-fold decreasing inhibitor concentrations ranging between 0.1nM and 10–100 mM 
(depending on the inhibitor potency, but at least five points at different inhibitor concentrations were 
employed for determining the inhibition constants). The uncatalyzed rates were determined in the 
same manner and subtracted from the total observed rates. Stock solutions of inhibitor (0.1 mM) were 
prepared in distilled-deionized water and dilutions up to 0.1 nM were done thereafter with the assay 
buffer. Inhibitor and enzyme solutions were preincubated together for 15 min at room temperature 
prior to assay, in order to allow for the formation of the E-I complex. The inhibition constants were 
obtained by non-linear least-squares methods using the Cheng–Prusoff equation, and represent the 
mean from three independent experiments. All human isoforms were recombinant enzymes produced 
as described earlier in our laboratory [33-35]. 
 
4.3. Cytotoxicity Assay 
4.3.1. Cell culture and treatments 
Human colon cancer cell lines HT-29 were obtained from American Type Culture Collection 
(Rockville, MD). HT-29 were cultured in DMEM high glucose with 20% FBS in 5% CO2 
atmosphere at 37° C. Media contained 2 mM L-glutamine, 1% essential amino acid mix, 100 IU ml
-
1
 penicillin and 100 μg ml
-1
 streptomycin (Sigma, Milan, Italy). HT-29 cells were plated in 96-




/well) and, 24 h after, treated with the tested compounds (0-300 µM) for 16, 
48 and 72 h. Low oxygen conditions were acquired in a hypoxic workstation (Concept 400 
anaerobic incubator, Ruskinn Technology Ltd., Bridgend, UK). The atmosphere in the chamber 
consisted of 0.1% O2 (hypoxia), 5% CO2, and residual N2. In parallel, normoxic (20% O2) dishes 
were incubated in air with 5% CO2. 
 
4.3.2. Cell viability assay 
HT-29 cell viability was evaluated by the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) as an index of mitochondrial compartment functionality. Cells 
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were plated and treated as described. After the treatment and extensive washing, 1 mg/ml MTT was 
added into each well and incubated for 30 minutes at 37 °C. After washing, the formazan crystals 
produced by the reaction were dissolved in 150 μl DMSO and the absorbance was measured at 550 
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